|
Scritto da BMC Ear, Nose and Throat Disorders - Latest articles
|
 Background:The 5G5G genotype of PAI-1 polymorphism is linked to decreased plasminogen activator inhibitor-1 (PAI-1) levels and it has been suggested that lower PAI-1 levels may provide protective effects on inflammation, local microcirculatory disturbance, and fibrotic changes, which are likely associated with development of SSNHL.Methods:The association of the 4 G/5 G PAI-1 polymorphism with the development and clinical outcome of sudden sensorineural hearing loss (SSNHL) is evaluated via a case control study. 103 patients with SSNHL and 113 age and sex-matched controls were enrolled at University of Ferrara, Italy and hearing loss outcome was measured at least 3 months after the onset of hearing loss. DNA was isolated from peripheral blood using the QIAamp kit and the 4 G/5 G polymorphism in the 675 promoter region was genotyped with an allele-specific PCR. Genotype distribution was tested in patients and compared to controls by chi-square and oddratio analysis. The codominant and recessive models were used for the multiple logistic regression analyses of the PAI-1 gene allele.Results:In this population, 5 G/5 G genotype had a two-time lower frequency in SSNHL patients compared to healthy controls (15.5 % vs 30.1 %) and was associated with decreased odds compared to 4 G/5 G genotype (OR 0.37, 95 % CI 0.19-0.75, p = 0.005). In addition, the patients with 5 G/5 G genotype showed a trend of more than 2 times higher ratio of hearing recovery (> 20 dB) after systemic corticosteroid treatment compared to 4 G/5 G genotype(OR 2.3, 95 % CI 0.32 - 16.83, p = 0.39), suggesting a better clinical outcome.Conclusions:The 5 G/5 G genotype of PAI-1 may be associated with a reduced risk of SSNHL in the Italian population.
Fonte: BMC Ear, Nose and Throat Disorders - Latest articles |
